Homocysteine induces mitochondrial dysfunction and oxidative stress in myocardial ischemia/reperfusion injury through stimulating ROS production and the ERK1/2 signaling pathway

Wang,Lei; Niu,Heping; Zhang,Jun

doi:10.3892/etm.2020.8735

Homocysteine induces mitochondrial dysfunction and oxidative stress in myocardial ischemia/reperfusion injury through stimulating ROS production and the ERK1/2 signaling pathway

Authors:
- Lei Wang
- Heping Niu
- Jun Zhang
View Affiliations

Affiliations: Department of Cardiology, Cangzhou Central Hospital, Cangzhou, Hebei 061001, P.R. China
Published online on: May 12, 2020 https://doi.org/10.3892/etm.2020.8735
Pages: 938-944
Copyright: © Wang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Acute oxidative stress and mitochondrial dysfunction are crucial for acute myocardial ischemia‑reperfusion (AMI/R) injury, which may induce cell or mitochondrial membrane rupture and myocardial infarction. Plasma homocysteine (Hcy) expression levels are positively associated with risk of cardiovascular disease, and ERK1/2 exert anti‑apoptotic and cardioprotective effects on AMI/R injury. However, the precise molecular mechanism of action underlying the effects of Hcy and the ERK1/2 signaling pathway on mitochondrial dysfunction and oxidative stress in AMI/R injury remains unclear. In the present study, AMI/R injury models were established in an animal model treated with Hcy and in H9C2 cells that were treated with hypoxia‑reoxygenation. Mitochondrial function and oxidative stress were evaluated. The results demonstrated that Hcy enhanced ERK1/2 protein expression levels and oxidative stress, induced cytochrome c translocation and mitochondria dysfunction, and caused cardiac dysfunction in rats with AMI/R injury. However, an ERK1/2 inhibitor effectively protected AMI/R injury rats from Hcy‑induced cardiac dysfunction and oxidative stress. In conclusion, Hcy induced mitochondrial dysfunction and oxidative stress in AMI/R injury through stimulating ROS production and the ERK1/2 signaling pathway. An ERK1/2 inhibitor may be an effective new therapeutic method for treating Hcy‑induced cardiac dysfunction in patients with AMI/R injury.

View Figures

View References

1	Thygesen K, Alpert JS, Jaffe AS, Simoons ML, Chaitman BR and White HD: Joint ESC/ACCF/AHA/WHF Task Force for Universal Definition of Myocardial Infarction; Authors/Task Force Members Chairpersons, Thygesen K, Alpert JS, et al. Third universal definition of myocardial infarction. J Am Coll Cardiol. 60:1581–1598. 2012.PubMed/NCBI View Article : Google Scholar
2	Hausenloy DJ and Yellon DM: Myocardial ischemia-reperfusion injury: A neglected therapeutic target. J Clin Invest. 123:92–100. 2013.PubMed/NCBI View Article : Google Scholar
3	Eltzschig HK and Eckle T: Ischemia and reperfusion-from mechanism to translation. Nat Med. 17(1391)2011.PubMed/NCBI View Article : Google Scholar
4	Yellon DM and Hausenloy DJ: Myocardial reperfusion injury. N Engl J Med. 357:1121–1135. 2007.PubMed/NCBI View Article : Google Scholar
5	Heusch G, Libby P, Gersh B, Yellon D, Böhm M, Lopaschuk G and Opie L: Cardiovascular in coronary artery disease and heart failure. Lancet. 383:1933–1943. 2014.PubMed/NCBI View Article : Google Scholar
6	Ganote C, Worstell J and Kaltenbach J: Oxygen-induced enzyme release after irreversible myocardial injury. Effects of cyanide in perfused rat hearts. Am J Pathol. 84:327–350. 1976.PubMed/NCBI
7	Zweier JL, Flaherty JT and Weisfeldt ML: Direct measurement of free radical generation following reperfusion of ischemic myocardium. Proc Natl Acad Sci USA. 84:1404–1407. 1987.PubMed/NCBI View Article : Google Scholar
8	Loor G, Kondapalli J, Iwase H, Chandel NS, Waypa GB, Guzy RD, Vanden Hoek TL and Schumacker PT: Mitochondrial oxidant stress triggers cell death in simulated ischemia-reperfusion. Biochim Biophys Acta. 1813:1382–1394. 2011.PubMed/NCBI View Article : Google Scholar
9	Murphy E and Steenbergen C: Mechanisms underlying acute protection from cardiac ischemia-reperfusion injury. Physiol Rev. 88:581–609. 2008.PubMed/NCBI View Article : Google Scholar
10	Di Lisa F and Bernardi P: Modulation of mitochondrial permeability transition in ischemia-reperfusion injury of the heart. Advantages and limitations. Curr Med Chem. 22:2480–2487. 2015.PubMed/NCBI View Article : Google Scholar
11	Paradies G, Petrosillo G, Pistolese M and Ruggiero FM: Reactive oxygen species affect mitochondrial electron transport complex I activity through oxidative cardiolipin damage. Gene. 286:135–141. 2002.PubMed/NCBI View Article : Google Scholar
12	Abe Ji, Baines CP and Berk BC: Role of mitogen-activated protein kinases in ischemia and reperfusion injury: The good and the bad. Circ Res. 86:607–609. 2000.PubMed/NCBI View Article : Google Scholar
13	Das A, Salloum FN, Xi L, Rao YJ and Kukreja RC: ERK phosphorylation mediates sildenafil-induced myocardial protection against ischemia-reperfusion injury in mice. Am J Physiol Heart Circ Physiol. 296:H1236–H1243. 2009.PubMed/NCBI View Article : Google Scholar
14	Yue TL, Wang C, Gu JL, Ma XL, Kumar S, Lee JC, Feuerstein GZ, Thomas H, Maleeff B and Ohlstein EH: Inhibition of extracellular signal-regulated kinase enhances ischemia/reoxygenation-induced apoptosis in cultured cardiac myocytes and exaggerates reperfusion injury in isolated perfused heart. Circ Res. 86:692–699. 2000.PubMed/NCBI View Article : Google Scholar
15	Di Cristo G, Berardi N, Cancedda L, Pizzorusso T, Putignano E, Ratto GM and Maffei L: Requirement of ERK activation for visual cortical plasticity. Science. 292:2337–2340. 2001.PubMed/NCBI View Article : Google Scholar
16	Wald DS, Law M and Morris JK: Homocysteine and cardiovascular disease: Evidence on causality from a meta-analysis. BMJ. 325(1202)2002.PubMed/NCBI View Article : Google Scholar
17	Ganguly P and Alam SF: Role of homocysteine in the development of cardiovascular disease. Nutri J. 14(6)2015.PubMed/NCBI View Article : Google Scholar
18	Malinow M, Levenson J, Giral P, Nieto F, Razavian M, Segond P and Simon A: Role of blood pressure, uric acid, and hemorheological parameters on plasma homocyst (e)ine concentration. Atherosclerosis. 114:175–183. 1995.PubMed/NCBI View Article : Google Scholar
19	Hoogeveen EK, Kostense PJ, Beks PJ, Mackaay AJ, Jakobs C, Bouter LM, Heine RJ and Stehouwer CD: Hyperhomocysteinemia is associated with an increased risk of cardiovascular disease, especially in non-insulin-dependent diabetes mellitus: A population-based study. Arterioscler Thromb Vasc Biol. 18:133–138. 1998.PubMed/NCBI View Article : Google Scholar
20	Shao L, Wu D, Zhang P, Li W, Wang J, Su G, Liao Y, Wang Z and Liu K: The significance of microthrombosis and fgl2 in no-reflow phenomenon of rats with acute myocardial ischemia/reperfusion. Clin Appl Thromb Hemost. 19:19–28. 2013.PubMed/NCBI View Article : Google Scholar
21	Leary S, Underwood W, Anthony R, Cartner S, Corey D, Grandin T, Greenacre C, Gwaltney-Brant S, McCrackin MA, Meyer R, et al: AVMA guidelines for the euthanasia of animals: 2013 edition.
22	Yin Y, Guan Y, Duan J, Wei G, Zhu Y, Quan W, Guo C, Zhou D, Wang Y, Xi M and Wen A: Cardioprotective effect of Danshensu against myocardial ischemia/reperfusion injury and inhibits apoptosis of H9c2 cardiomyocytes via Akt and ERK1/2 phosphorylation. Eur J Pharmacol. 699:219–226. 2013.PubMed/NCBI View Article : Google Scholar
23	Feigin VL, Forouzanfar MH, Krishnamurthi R, Mensah GA, Connor M, Bennett DA, Moran AE, Sacco RL, Anderson L, Truelsen T, et al: Global and regional burden of stroke during 1990-2010: Findings from the Global Burden of Disease Study 2010. Lancet. 383:245–255. 2014.PubMed/NCBI View Article : Google Scholar
24	Scarabelli TM, Stephanou A, Pasini E, Comini L, Raddino R, Knight RA and Latchman DS: Different signaling pathways induce apoptosis in endothelial cells and cardiac myocytes during ischemia/reperfusion injury. Circ Res. 90:745–748. 2002.PubMed/NCBI View Article : Google Scholar
25	Xu Q, Li X, Lu Y, Shen L, Zhang J, Cao S, Huang X, Bin J and Liao Y: Pharmacological modulation of autophagy to protect cardiomyocytes according to the time windows of ischaemia/reperfusion. Br J Pharmacol. 172:3072–3085. 2015.PubMed/NCBI View Article : Google Scholar
26	Kim SJ, Yoo KY, Jeong CW, Kim WM, Lee HK, Bae HB, Kwak SH, Li M and Lee J: Urinary trypsin inhibitors afford cardioprotective effects through activation of PI3K-Akt and ERK signal transduction and inhibition of p38 MAPK and JNK. Cardiology. 114:264–270. 2009.PubMed/NCBI View Article : Google Scholar
27	Hassan A, Hunt BJ, O'sullivan M, Bell R, D'souza R, Jeffery S, Bamford JM and Markus HS: Homocysteine is a risk factor for cerebral small vessel disease, acting via endothelial dysfunction. Brain. 127:212–219. 2004.PubMed/NCBI View Article : Google Scholar
28	Misra HP: Generation of superoxide free radical during the autoxidation of thiols. J Biol Chem. 249:2151–2155. 1974.PubMed/NCBI
29	Majors A, Ehrhart LA and Pezacka EH: Homocysteine as a risk factor for vascular disease. Enhanced collagen production and accumulation by smooth muscle cells. Arterioscler Thromb Vasc Biol. 17:2074–2081. 1997.PubMed/NCBI View Article : Google Scholar
30	Basu A, Jenkins AJ, Stoner JA, Thorpe SR, Klein RL, Lopes-Virella MF, Garvey WT and Lyons TJ: DCCT/EDIC Research Group. Plasma total homocysteine and carotid intima-media thickness in type 1 diabetes: A prospective study. Atherosclerosis. 236:188–195. 2014.PubMed/NCBI View Article : Google Scholar
31	Zhang S, Bai YY, Luo LM, Xiao WK, Wu HM and Ye P: Association between serum homocysteine and arterial stiffness in elderly: A community-based study. J Geriatr Cardiol. 11:32–38. 2014.PubMed/NCBI View Article : Google Scholar
32	Balakumar P, Singh AP and Singh M: Rodent models of heart failure. J Pharmacol Toxicol Methods. 56:1–10. 2007.PubMed/NCBI View Article : Google Scholar
33	Purcell NH, Wilkins BJ, York A, Saba-El-Leil MK, Meloche S, Robbins J and Molkentin JD: Genetic inhibition of cardiac ERK1/2 promotes stress-induced apoptosis and heart failure but has no effect on hypertrophy in vivo. Proc Natl Acad Sci USA. 104:14074–14079. 2007.PubMed/NCBI View Article : Google Scholar
34	Bueno OF, De Windt LJ, Tymitz KM, Witt SA, Kimball TR, Klevitsky R, Hewett TE, Jones SP, Lefer DJ, Peng CF, et al: The MEK1-ERK1/2 signaling pathway promotes compensated cardiac hypertrophy in transgenic mice. EMBO J. 19:6341–6350. 2000.PubMed/NCBI View Article : Google Scholar